MOTS-c
MOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway. Human evidence remains observational: Zhou 2024 pooled seven biomarker studies, but no published human RCT has tested exogenous MOTS-c for clinical outcomes.
MOTS-c scored 5.5 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Peptide → Other Peptide.
What It Is
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded inside the mitochondrial 12S rRNA region. The core finding from Lee 2015 is that MOTS-c can regulate insulin sensitivity and metabolic homeostasis by inhibiting the folate and purine biosynthesis pathway, raising AICAR, and activating AMPK, the same energy-sensing pathway stimulated by exercise and caloric stress.
That makes MOTS-c one of the more interesting research peptides in the mitochondrial category. Kim 2018 showed that MOTS-c can translocate to the nucleus during metabolic stress and regulate adaptive stress-response genes. Reynolds 2021 connected MOTS-c to exercise-induced signaling in humans and physical-capacity biology in mice. The problem is translation: no published human interventional RCT has administered exogenous MOTS-c and measured clinical metabolic, endurance, body-composition, or longevity outcomes through the audit date.
The practical version sold online is not an approved medicine. It is usually a lyophilized research peptide that users reconstitute and inject subcutaneously. The upside case is compelling for older, sedentary, insulin-resistant, or metabolically unhealthy people because the preclinical biology points directly at AMPK, glucose disposal, adipose function, and exercise-like metabolic adaptation. The downside case is equally clear: FDA compounding safety-risk language and WADA's prohibited-list status mean MOTS-c should be treated as a gray-market experimental peptide, not a normal supplement.
Terminology
- MOTS-c: Mitochondrial open reading frame of the 12S rRNA type-c. A 16-amino-acid peptide encoded in mitochondrial DNA.
- MDP: Mitochondrial-derived peptide. A small peptide encoded by the mitochondrial genome. The family includes MOTS-c, humanin, and SHLP 1-6.
- Humanin: A 24-amino-acid MDP encoded in the 16S rRNA region, generally discussed for anti-apoptotic and neuroprotective signaling.
- SHLP: Small humanin-like peptide. A family of short mitochondrial-derived peptides with varied metabolic and stress-response effects.
- AMPK: AMP-activated protein kinase. A cellular energy sensor activated by low energy availability, exercise, metformin, AICAR, and MOTS-c pathway signaling.
- ATIC: A bifunctional enzyme in de novo purine biosynthesis that MOTS-c inhibits in the Lee model.
- AICAR: A purine-pathway intermediate and AMPK activator that accumulates when ATIC activity is inhibited.
- mtDNA: Mitochondrial DNA. The small circular genome inside mitochondria.
- 12S rRNA: Mitochondrial ribosomal RNA region where the MOTS-c open reading frame is encoded.
- Exercise mimetic: A compound that triggers some exercise-like cellular signals without the full mechanical, cardiovascular, and neuromuscular work of exercise.
- CB4211: CohBar's MOTS-c analog developed for NASH and obesity. It is not the same as gray-market MOTS-c.
- Gray-market peptide: A research-chemical peptide sold outside normal FDA-approved prescription, pharmacy, or dietary-supplement channels.
- K14Q: A lysine-to-glutamine MOTS-c variant at position 14, also described as m.1382A>C in mitochondrial DNA.
- WADA: World Anti-Doping Agency. WADA lists MOTS-c as a prohibited AMPK activator under metabolic modulators.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 2 routes and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Subcutaneous injection (gray-market) | Reconstituted lyophilized peptide powder with bacteriostatic water; 27-30g insulin syringe; abdomen or thigh injection | No human clinical range. Mouse studies used intraperitoneal dosing such as 0.5 mg/kg/day in high-fat-diet models and 5 mg/kg/day in some glucose-handling experiments. Preclinical-only dose extrapolation. Lee 2015 mouse dose roughly maps to low single-digit milligrams for a 70 kg human by standard body-surface conversion, but this is not a validated human dose. | 5-10 mg per injection, 3x/week; minority protocols use 1-2 mg daily Common in private peptide forums and N=1 tracking communities; not supported by RCT data. |
| Intranasal (gray-market) | Research-peptide nasal spray or self-compounded nasal solution | None. No intranasal MOTS-c human clinical data. No pharmacokinetic or bioavailability validation for intranasal MOTS-c. | 2-5 mg per dose, variable frequency Needle-averse minority route with uncertain absorption. |
Protocols
Standard metabolic / longevity protocol Anecdotal
- Dose
- 5-10 mg SC
- Frequency
- 3x/week
- Duration
- 4-8 weeks on, then 4 weeks off
Most common community protocol. Cycling is precautionary, not evidence-based.
Post-exercise timing Anecdotal
- Dose
- 5 mg SC
- Frequency
- Within 60 minutes post-workout, up to 3x/week
- Duration
- 4-8 weeks
[Reynolds 2021](https://pubmed.ncbi.nlm.nih.gov/33473109/) showed exercise induces endogenous MOTS-c in humans, but no trial compares post-workout dosing to other timing.
Cycling (4 on / 4 off) Anecdotal
- Dose
- 5 mg SC 3x/week
- Frequency
- 3x/week during on-cycle, then no dosing during washout
- Duration
- Indefinite cycling if continued
Used to avoid theoretical tolerance. No human tachyphylaxis, suppression, or washout data exists.
Stacked with humanin Anecdotal
- Dose
- MOTS-c 5 mg SC 3x/week plus humanin 2.5-5 mg SC 2-3x/week
- Frequency
- Alternating days
- Duration
- 4-8 weeks
Community MDP stack. Mechanistic rationale exists, but no head-to-head or combination trial supports it.
SS-31 then MOTS-c sequence Anecdotal
- Dose
- SS-31 cycle first, then MOTS-c 5 mg SC 3x/week
- Frequency
- Sequential cycles
- Duration
- SS-31 4-8 weeks, then MOTS-c 4-8 weeks
Nick's preferred sequence: SS-31 first for mitochondrial membrane support, then MOTS-c for AMPK signaling.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
Upside contribution: 2.25
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.0 | 0.500 | |
| Breadth of Benefits | 15% | 3.5 | 0.525 | |
| Evidence Quality | 25% | 1.8 | 0.450 | |
| Speed of Onset | 10% | 2.5 | 0.250 | |
| Durability | 10% | 1.5 | 0.150 | |
| Bioindividuality Upside | 15% | 2.5 | 0.375 | |
| Total | 2.250 |
Upside Rationale
MOTS-c has real upside when the use case matches its best evidence, especially around mitochondrial, metabolic health, blood sugar, energy. Lee 2015 and Kim 2018 support the main positive signal, but the useful part is not the headline mechanism. It is the chance to connect MOTS-c to a measurable outcome and see whether the expected change appears. The upside is strongest for users with the relevant baseline problem, weaker for optimized users chasing a vague edge, and most honest when paired with tracking. For this report, MOTS-c earns credit for plausible mechanisms, human or clinical anchors where available, and practical fit. The right read is targeted use, not automatic daily inclusion.
Efficacy (2.0/5.0). MOTS-c has strong mouse efficacy and no published human interventional efficacy RCT. Lee 2015 showed MOTS-c improved metabolic homeostasis, insulin sensitivity, and diet-induced obesity biology in mice, while Reynolds 2021 showed exercise-induced MOTS-c signaling in humans and physical-capacity effects in mice. Zhou 2024 upgraded the human evidence to biomarker meta-analysis level, but that still measures circulating MOTS-c associations, not clinical outcomes after dosing. The efficacy score stays 2.0 because every meaningful dosing claim for glucose control, endurance, body composition, and longevity remains extrapolated from preclinical or observational evidence.
Breadth of Benefits (3.5/5.0). MOTS-c touches a wide mechanistic surface: glucose disposal, insulin sensitivity, adipose homeostasis, exercise response, muscle homeostasis, bone remodeling, inflammation, stress-response gene expression, and age-related metabolic resilience. Lu 2019 supports adipose effects in ovariectomized mice; Ming 2016 supports bone-loss biology; Zhai 2017 supports immunometabolic anti-inflammatory effects in an MRSA mouse model. The breadth score is materially higher than efficacy because AMPK sits upstream of many systems. But the breadth is still preclinical. MOTS-c does not yet have human benefit evidence across these systems.
Evidence Quality (1.8/5.0). MOTS-c evidence quality is limited by a central missing piece: no published human RCT of exogenous MOTS-c. Kim 2018 and Benayoun 2019 strengthen mechanistic credibility, and Miller 2022 places MOTS-c within the broader MDP healthspan literature. But the key preclinical work is concentrated around a relatively small research ecosystem, CohBar's CB4211 program did not produce peer-reviewed Phase 2 efficacy evidence, and FDA's MOTs-C compounding warning underscores the human-exposure gap. Zhou 2024 helps biomarker confidence but does not justify an evidence-score upgrade.
Speed of Onset (2.5/5.0). MOTS-c has moderately fast preclinical onset but unknown human kinetics. Lee 2015 showed short-course mouse metabolic changes under controlled dosing, and community users often evaluate subjective energy over 1-4 weeks. The uncertainty is pharmacokinetic: no human half-life, peak-time, bioavailability, or tissue-exposure study has defined what injected MOTS-c does after administration. Exercise biology from Reynolds 2021 supports acute endogenous MOTS-c responsiveness, but endogenous exercise response is not the same as exogenous peptide dosing. The score stays 2.5 because onset may be fast, but human timing is still guessed.
Durability (1.5/5.0). MOTS-c durability is unknown because no published washout data exists for exogenous use. The strongest assumption is that any benefit requires repeated dosing or repeated endogenous stimulation through exercise, fasting, or other metabolic stressors. Users commonly cycle 4-8 weeks on and 4 weeks off, but that pattern is precautionary rather than evidence-based. There is no published human data showing whether a MOTS-c course leaves lasting improvements in insulin sensitivity, muscle function, adipose biology, or energy after cessation. The durability score remains low because MOTS-c may act more like a transient signal than a durable adaptation.
Bioindividuality Upside (2.5/5.0). MOTS-c probably works best in people with a low-baseline metabolic signal: older adults, sedentary adults, insulin-resistant people, and people with impaired exercise capacity. Zhou 2024 shows circulating MOTS-c varies across metabolic states, and Fuku 2015 suggests genetic variation may matter. In practice, trained and insulin-sensitive users may already generate strong endogenous MOTS-c responses through exercise, so marginal benefit could be small. The bioindividuality score stays 2.5 because responder logic is coherent, but no prospective biomarker tells a user whether MOTS-c will work for them.
Downside contribution: 1.76 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.2 | 0.360 | |
| Side Effect Profile | 15% | 1.3 | 0.195 | |
| Financial Cost | 5% | 3.0 | 0.150 | |
| Time/Effort Burden | 5% | 3.0 | 0.150 | |
| Opportunity Cost | 5% | 2.5 | 0.125 | |
| Dependency / Withdrawal | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.0 | 0.250 | |
| Total | 1.380 | |||
| Harm subtotal × 1.4 | 1.337 | |||
| Opportunity subtotal × 1.0 | 0.425 | |||
| Combined downside | 1.762 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.422 |
Downside Rationale
MOTS-c's downside is the gap between plausible benefit and the cost, risk, or uncertainty required to test it. Lee 2015 and Kim 2018 frame the caution side better than mechanism talk alone. The main issue may be safety, supervision, legality, product quality, opportunity cost, or simply weak evidence outside the best-matched population. MOTS-c deserves extra caution when users are pregnant, medically complex, competing under drug rules, taking interacting medications, or trying to replace proven care. The practical orientation is simple: start with the lowest-risk version of the intervention, keep the trial time-bound, and stop when side effects, unclear benefit, or better alternatives show up. Lee 2015 is the cleanest anchor here: discovery paper; MOTS-c encoded in mitochondrial 12S rRNA; AMPK activation via folate and purine pathway; mouse metabolic effects.
Safety Risk (1.2/5.0). MOTS-c intrinsic safety still looks relatively clean preclinically, but human regulatory safety confidence is weaker than the old gray-market framing implied. FDA lists MOTs-C among bulk substances that may present significant safety risks for compounding, citing immunogenicity, peptide-related impurities, API characterization complexity, and lack of identified human exposure data. No organ-toxicity signal dominates the published animal literature, and community reports are mostly injection-site irritation and fatigue. The score stays 1.2 because no intrinsic severe toxicity signal was verified, but the v1.0 wording now separates clean preclinical mechanism from unregulated product risk.
Side Effect Profile (1.3/5.0). MOTS-c side effects appear mild in community use, but they are not measured in a proper placebo-controlled human MOTS-c trial. The common pattern is injection-site redness, transient swelling, and occasional early-cycle fatigue. Unlike GH secretagogues or IGF-axis peptides, MOTS-c does not have a known endocrine side-effect signature. Still, absence of published controlled human dosing means low-frequency reactions, immune reactions, and formulation-related effects could be missed. The side-effect score stays 1.3 because observed real-world nuisance effects look low, while FDA's peptide impurity and immunogenicity concerns keep the certainty low.
Financial Cost (3.0/5.0). MOTS-c is a mid-cost peptide, usually $100-200/month from research vendors before supplies. Syringes, bacteriostatic water, alcohol swabs, sharps disposal, and occasional cold-chain shipping add modest cost. There is no insurance coverage, no approved prescription channel, and no legal compounding pathway equivalent to approved drugs. The score stays 3.0 because MOTS-c is cheaper than many clinic peptides but still meaningfully more expensive than established metabolic basics such as metformin, creatine, protein, sleep tracking, or a basic gym membership.
Time/Effort Burden (3.0/5.0). MOTS-c requires meaningful logistics: vial reconstitution, refrigerated storage, sterile handling, subcutaneous injections, site rotation, dosing calendar, travel planning, and sharps disposal. The injection itself is quick, but the setup burden is real for users not already comfortable with peptides. MOTS-c is much more effort than oral mitochondrial supplements such as urolithin A and more complex than exercise or nutrition tracking once those routines are established. The score stays 3.0 because protocol friction can determine adherence as much as biology.
Opportunity Cost (2.5/5.0). MOTS-c has a real opportunity-cost question: could the same budget and attention go to exercise, nutrition, sleep, or proven metabolic care? Since MOTS-c is an exercise mimetic, the cleanest alternative is still exercise itself. For someone who can train, progressive zone 2, resistance training, and post-meal walks produce broader adaptations than isolated AMPK nudging. For older, sedentary, injured, or metabolically compromised users who cannot fully train, the opportunity cost is lower. The score stays 2.5 because MOTS-c can stack with the basics, but it can also distract from them.
Dependency/Withdrawal (1.0/5.0). MOTS-c has no known dependency or withdrawal signal. There is no known receptor downregulation, HPA-axis suppression, craving pattern, or rebound syndrome from stopping MOTS-c. Community users who cycle on and off generally describe a return to baseline rather than withdrawal. The main unknown is not addiction; it is whether exogenous dosing changes endogenous MOTS-c dynamics over time. No human study has tested that. The dependency score remains 1.0 because current mechanism and reports do not support dependence.
Reversibility (1.0/5.0). MOTS-c appears fully reversible based on current evidence. Stopping should remove the exogenous signal once the peptide clears, leaving baseline AMPK activation to exercise, nutrition, fasting, age, and metabolic health. No permanent tissue remodeling, receptor adaptation, or persistent gene-expression change has been documented from exogenous human use. The unknown human half-life does not change the reversibility judgment because no evidence suggests irreversible biological change. The score remains 1.0, with the caveat that no formal human washout study exists.
Verdict
MOTS-c is a 5.5/10 fit for people considering mitochondrial, metabolic health, blood sugar, energy, with the strongest case in the populations already represented by the evidence rather than broad wellness use. Lee 2015 and Kim 2018 give the report its main anchors, while the score stays neutral because benefits are context-dependent and the evidence still leaves responder, dose, and long-term questions open. MOTS-c makes the most sense when the target is concrete, such as a lab marker, symptom pattern, training limitation, or recovery bottleneck. It makes less sense as a background habit taken on faith. In practice, treat MOTS-c as a tracked experiment: define the outcome first, watch for tradeoffs, and let the response decide whether it earns a place.
✅ Best for: Metabolically unhealthy, sedentary, or aging adults who accept a research-peptide risk profile and want to test an exercise-mimetic AMPK signal while tracking objective biomarkers. MOTS-c is most relevant when fasting glucose, insulin resistance, body composition, fatigue, or low exercise capacity are the target, and especially when the user already has sleep, protein, resistance training, and low-intensity cardio basics in place. MOTS-c also fits advanced mitochondrial protocols where SS-31 comes first and MOTS-c follows as a signaling layer.
❌ Avoid if: You require human clinical-trial evidence before using an intervention, compete in tested sport, are pregnant or lactating, have active cancer involving mitochondrial or metabolic vulnerability, use glucose-lowering medication without clinician oversight, or cannot verify peptide source quality. MOTS-c is also a poor fit if you are healthy, trained, and insulin-sensitive, because exercise already induces endogenous MOTS-c signaling. Avoid MOTS-c if injection sterility, refrigeration, reconstitution, and sharps disposal feel like too much friction.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Mitochondrial: 6.5/10
Score: 6.5/10MOTS-c earns 6.5/10 for mitochondrial; this is a targeted fit score. Core mechanism: MOTS-c is a mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through ATIC inhibition and AICAR accumulation, improving mitochondrial-linked work output and metabolic stress adaptation in preclinical systems. That makes MOTS-c more defensible when mitochondrial is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the mitochondrial marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Metabolic Health: 6.0/10
Score: 6.0/10For metabolic health, MOTS-c lands at 6.0/10 because context matters. Lee 2015 showed MOTS-c improved insulin sensitivity and diet-induced obesity measures in mice, while Zhou 2024 found circulating MOTS-c differs by metabolic state in humans. No exogenous human trial exists. That makes MOTS-c more defensible when metabolic health is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the metabolic health marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Blood Sugar / Glycemic Control: 6.0/10
Score: 6.0/10MOTS-c gets 6.0/10 for blood sugar; the evidence supports a narrow read. MOTS-c blood-sugar support comes from AMPK-mediated glucose disposal and mouse insulin-sensitivity findings in Lee 2015. Human data remains biomarker-observational, not dosing-interventional. That makes MOTS-c more defensible when blood sugar is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the blood sugar marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Energy / Fatigue: 5.0/10
Score: 5.0/10MOTS-c fits energy at 5.0/10 when the baseline problem is real. MOTS-c earns an energy score from exercise-mimetic AMPK activation, Reynolds 2021 exercise biology, and Nick's subjective energy response. Human energy endpoints remain unvalidated. That makes MOTS-c more defensible when energy is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the energy marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Endurance / Cardio: 5.0/10
Score: 5.0/10The endurance cardio score is 5.0/10, and MOTS-c needs careful framing. MOTS-c earns an endurance-cardio signal from exercise-mimetic AMPK activation and mouse physical-capacity findings in Reynolds 2021, but no human VO2max, time-trial, or endurance RCT exists. That makes MOTS-c more defensible when endurance cardio is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the endurance cardio marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Body Composition / Fat Loss: 5.5/10
Score: 5.5/10For readers prioritizing body composition, MOTS-c scores 5.5/10 today. Lee 2015 showed diet-induced obesity prevention in mice, and Lu 2019 showed ovariectomy-related adipose protection in mice. Human body-composition data from exogenous MOTS-c remains absent. That makes MOTS-c more defensible when body composition is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the body composition marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
Geriatric / Aging Population: 5.0/10
Score: 5.0/10The 5.0/10 geriatric score reflects evidence plus practical constraints. Geriatric relevance is stronger because endogenous MOTS-c changes with age and Reynolds 2021 tested late-life mouse physical-capacity effects. Human geriatric intervention trials remain absent. That makes MOTS-c more defensible when geriatric is a real bottleneck and less compelling when basics already cover the same ground. The practical test is narrow: define the geriatric marker, run a time-bound trial, and stop if the signal is absent or side effects appear.
| Use Case | Score | Summary |
|---|---|---|
| ○ Longevity / Lifespan Primary | 4.0 | Fuku 2015 associated a MOTS-c polymorphism with exceptional longevity in Japanese centenarians, and endogenous levels relate to aging biology. No lifespan-extension study from exogenous MOTS-c exists. |
| ○ Anti-Inflammatory | 4.5 | Zhai 2017 showed anti-inflammatory and anti-MRSA effects in mice, including reduced pro-inflammatory cytokine signaling. This supports a preclinical inflammation signal but not a human anti-inflammatory indication. |
| ○ Healthspan | 4.0 | MOTS-c touches healthspan-relevant pathways including metabolic health, exercise capacity, inflammation, and muscle homeostasis. Miller 2022 reviews MDP healthspan biology, but clinical translation remains early. |
| ○ Bone / Joint Health | 3.5 | Ming 2016 showed MOTS-c suppressed ovariectomy-induced bone loss through AMPK activation in mice, supporting a preclinical bone signal. The score stays 3.5 because no human osteoporosis, joint, or fracture trial exists. |
| ○ Recovery / Repair | 3.5 | MOTS-c may support recovery through AMPK and mitochondrial optimization, but recovery-repair evidence is theoretical and preclinical. No MOTS-c trial measures soreness, training readiness, injury return, or recovery biomarkers in humans. |
| ○ Cardiovascular | 3.0 | AMPK activation has cardioprotective downstream effects, but MOTS-c has no direct cardiovascular RCT. The cardiovascular score stays low because support is indirect, mostly from metabolic pathway reasoning and diabetic animal models rather than human outcomes. |
| ○ Muscle Growth / Hypertrophy | 3.0 | MOTS-c is not primarily anabolic. AMPK activation can compete with mTOR-driven hypertrophy signaling, so muscle-growth claims should stay modest despite Reynolds 2021 muscle-homeostasis data. |
Frequently Asked Questions
What is MOTS-c and how does it work?
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA that activates AMPK through the folate and purine biosynthesis pathway. Lee 2015 identified MOTS-c and showed that its cellular actions inhibit ATIC, raise AICAR, and activate AMPK. Kim 2018 later showed MOTS-c can move into the nucleus during metabolic stress and regulate stress-response genes.
What does the animal vs human evidence actually look like?
MOTS-c has strong animal evidence and weak human intervention evidence. Lee 2015 and Reynolds 2021 support mouse metabolic and physical-capacity effects, and Reynolds also showed exercise-induced endogenous MOTS-c in humans. Zhou 2024 pooled human biomarker studies, but no published human RCT has dosed exogenous MOTS-c and measured clinical outcomes.
What happened to CohBar's MOTS-c drug program?
CohBar developed CB4211, a MOTS-c analog, for NASH and obesity, but that program never produced peer-reviewed Phase 2 efficacy evidence. The ClinicalTrials.gov CB4211 record documents the regulated trial pathway, but audit review found no peer-reviewed full-paper result establishing clinical benefit. This leaves MOTS-c itself in a gray-market N=1 world rather than a validated therapeutic channel.
How do biohackers actually dose MOTS-c?
The common community protocol is 5-10 mg subcutaneous injection 3x/week for 4-8 weeks, often followed by a 4-week washout. That protocol is not clinical. It is extrapolated from animal work such as Lee 2015 and then amplified by peptide forums. No human pharmacokinetic study defines half-life, bioavailability, dose-response, or long-term dosing cadence.
Is MOTS-c really a longevity drug or just hype?
MOTS-c is a healthspan-relevant peptide, not a proven longevity drug. Fuku 2015 linked the K14Q / m.1382A>C MOTS-c variant with exceptional longevity in Japanese centenarians, and Reynolds 2021 supports age-related physical-capacity biology in mice. But no study shows that exogenous MOTS-c extends lifespan in humans or animals.
How do real people use MOTS-c in stacks?
The most common advanced stack is SS-31 first, then MOTS-c, based on the idea that mitochondrial membrane support should precede AMPK signaling. Nick uses that sequence, and the related SS-31 report covers the upstream mitochondrial membrane angle. Other community stacks pair MOTS-c with humanin or time injections after training because Reynolds 2021 showed exercise induces endogenous MOTS-c.
What are the safety concerns with gray-market MOTS-c?
MOTS-c looks intrinsically low-toxicity in preclinical work, but gray-market human use has real safety gaps. FDA lists MOTs-C among bulk substances that may present significant safety risks, citing immunogenicity, peptide impurities, API characterization complexity, and lack of human exposure data. Practical risks include contamination, inaccurate vial content, poor sterility, and reconstitution errors.
What is the MDP family and how is MOTS-c related to humanin and SHLP?
MOTS-c belongs to the mitochondrial-derived peptide family, small peptides encoded in mitochondrial DNA rather than nuclear DNA. Benayoun 2019 places MOTS-c in the nucleus-regulating MDP context, while Miller 2022 reviews humanin, MOTS-c, and SHLPs as aging and healthspan signals. Community stacking is mechanistic extrapolation, not validated combination therapy.
Can athletes use MOTS-c?
Tested athletes should avoid MOTS-c. WADA lists mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) as an example of an AMPK activator under S4.4 metabolic modulators. That means MOTS-c is prohibited in sport independent of whether the product is sold online as a research peptide or supplement-like compound.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| First human interventional RCT confirms metabolic benefits | Evidence 1.8 to 3.0, Efficacy 2.0 to 3.0 | 6.9 / 10 💪 Strong recommend |
| Human pharmacokinetic study establishes half-life and optimal dose | Evidence 1.8 to 2.5 | 6.3 / 10 👍 Worth trying |
| Independent lab fails to replicate Lee 2015 metabolic results | Evidence 1.8 to 1.2, Efficacy 2.0 to 1.5 | 5.1 / 10 👍 Worth trying |
| Long-term safety concern emerges from 5+ year community or registry data | Safety 1.2 to 2.5 | 5.1 / 10 👍 Worth trying |
| CohBar successor sponsor advances a MOTS-c analog to Phase 2 with positive biomarkers | Evidence 1.8 to 2.6, Efficacy 2.0 to 2.5 | 6.5 / 10 💪 Strong recommend |
| Head-to-head versus urolithin A shows equivalent mitochondrial endpoints with oral dosing | Efficacy 2.0 to 2.3, Opportunity Cost 2.5 to 3.2 | 5.6 / 10 👍 Worth trying |
Key Evidence Sources
- Lee C et al. 2015 - The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance, Cell Metabolism. Discovery paper; MOTS-c encoded in mitochondrial 12S rRNA; AMPK activation via folate and purine pathway; mouse metabolic effects
- Kim KH et al. 2018 - The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress, Cell Metabolism. Corrected PMID; shows AMPK-dependent nuclear translocation and stress-response gene regulation
- Reynolds JC et al. 2021 - MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis, Nature Communications. Corrected PMID; exercise-induced endogenous MOTS-c in humans and physical-capacity findings in mice
- Zhou Q et al. 2024 - The correlation between mitochondrial derived peptide and metabolic states: systematic review and meta-analysis, Diabetology & Metabolic Syndrome. Seven human biomarker studies; diabetes subgroup lower MOTS-c, obesity subgroup direction differs after analysis
- Fuku N et al. 2015 - The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?, Aging Cell. K14Q / m.1382A>C MOTS-c variant associated with exceptional longevity hypothesis in Japanese population
- Lu H et al. 2019 - MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction, Journal of Molecular Medicine. Corrected PMID; ovariectomy mouse metabolic dysfunction, adipose homeostasis, AMPK pathway
- Ming W et al. 2016 - Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation, Biochemical and Biophysical Research Communications. Corrected title and journal from audit; ovariectomy-induced bone-loss mouse model
- Zhai D et al. 2017 - MOTS-c peptide increases survival and decreases bacterial load in mice infected with MRSA, Molecular Immunology. Corrected PMID; MRSA mouse survival, bacterial load, and inflammatory cytokine direction
- Benayoun BA and Lee C 2019 - MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus, BioEssays. Corrected BioEssays record; MDP and mitonuclear gene-regulation context
- Miller B et al. 2022 - Mitochondria-derived peptides in aging and healthspan, Journal of Clinical Investigation. MDP review covering humanin, MOTS-c, SHLPs, aging, and healthspan therapeutic context
- Gao Y et al. 2023 - MOTS-c Functionally Prevents Metabolic Disorders, Metabolites. Open-access review summarizing MOTS-c pathways, metabolic findings, and gene targets
- Yen K and Cohen P 2019 - MOTS-c: an equal opportunity insulin sensitizer, Aging. Commentary on insulin-sensitizing context and MOTS-c as mitochondrial signaling peptide
- ClinicalTrials.gov 2020 - CB4211 Phase 1a/1b study in NASH and obesity, NCT04364737. Closest regulated MOTS-c analog program; not direct exogenous MOTS-c efficacy evidence
- FDA 2026 - Certain bulk drug substances for use in compounding that may present significant safety risks. FDA lists MOTs-C with immunogenicity, peptide impurity, API characterization, and lack-of-human-exposure concerns
- WADA 2026 - Prohibited List: S4.4 metabolic modulators. Lists MOTS-c as an example of prohibited AMPK activators
- Du C et al. 2018 - Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance, Pediatric Diabetes. Corrected away from unrelated v0.x PMID; pediatric obesity observational biomarker evidence
- Luo YH et al. 2023 - Serum MOTS-C levels are decreased in obese children and associated with vascular endothelial function, Diabetes, Metabolic Syndrome and Obesity. Human pediatric observational study linking serum MOTS-C with obesity and vascular endothelial function markers
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Limited
Citations: Lee 2015, Kim 2018, Reynolds 2021, Zhou 2024, Fuku 2015, FDA 2026, WADA 2026
Pre-RCT-Era Pharmacology and Use
Confidence: Limited
Citations: Humanin 2001, Lee 2015, CohBar CB4211 program, Miller 2022
Traditional Medicine Systems
Confidence: Low
Holistic Evidence for MOTS-c
The lenses mostly diverge. Modern science shows a real mitochondrial peptide with AMPK and stress-response activity, but human dosing evidence is missing. Historical evidence shows a young discovery pipeline, not mature clinical use. Traditional practice supports exercise, fasting, and metabolic stress as resilience builders, but not isolated MOTS-c injection. Honest synthesis: MOTS-c is a promising mechanistic peptide for narrow, informed experimentation, not a validated replacement for exercise, metabolic treatment, or regulated peptide therapy.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- HbA1c Baseline (pre-protocol)
- Fasting Glucose During | Expected Down
- Fasting Insulin During | Expected Down
- Triglycerides During | Expected Down
- Lactate Baseline (pre-protocol) During | Expected Down
- hs-CRP During | Expected Down
- ALT During | Expected Stable
- AST During | Expected Stable
- WBC During | Expected Stable
Pulse Dimensions to Watch
- Energy During | Expected Up | Primary
- Body During | Expected Up | Primary
- Drive During | Expected Up | Secondary
Subjective Signals (Daily Voice Card)
- Exercise Tolerance Scale 1-5 | During | Expected Up
- Injection-Site Irritation Scale 1-5 | During | Expected Watch
- Appetite Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Injection-site infection
- Hypoglycemia symptoms
- Severe fatigue or muscle weakness
Other interventions for Mitochondrial
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.250 − 0.422 = 0.828
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.828 / 5) × 5 = 5.8 / 10
